These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19808868)

  • 1. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
    Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
    Zhu J; Lallemand-Breitenbach V; de Thé H
    Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U; Pelosi E
    Adv Exp Med Biol; 2024; 1459():321-339. PubMed ID: 39017850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
    Kamashev D; Vitoux D; De Thé H
    J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
    Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
    de Thé H; Pandolfi PP; Chen Z
    Cancer Cell; 2017 Nov; 32(5):552-560. PubMed ID: 29136503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
    Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.
    Mozziconacci MJ; Rosenauer A; Restouin A; Fanelli M; Shao W; Fernandez F; Toiron Y; Viscardi J; Gambacorti-Passerini C; Miller WH; Lafage-Pochitaloff M
    Genes Chromosomes Cancer; 2002 Nov; 35(3):261-70. PubMed ID: 12353268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells.
    Nason-Burchenal K; Takle G; Pace U; Flynn S; Allopenna J; Martin P; George ST; Goldberg AR; Dmitrovsky E
    Oncogene; 1998 Oct; 17(14):1759-68. PubMed ID: 9778041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms.
    Pollock JL; Lane AA; Schrimpf K; Ley TJ
    Haematologica; 2005 Aug; 90(8):1042-9. PubMed ID: 16079103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.